Oryx Pharmaceuticals

Oryx (Oryx GmbH & Co. KG) is a clinical-stage biotechnology company based in Germany that specializes in the development of innovative oncolytic virus therapies and therapeutic cancer vaccines. The company's pipeline is primarily derived from academic research at the German Cancer Research Center (DKFZ) and the University of Heidelberg, focusing on high-unmet-need oncology indications. Its lead candidate, ParvOryx, is an oncolytic H-1 parvovirus being evaluated for the treatment of glioblastoma and pancreatic cancer. Additionally, Oryx is advancing two vaccine programs: VicOryx, which targets p16INK4a-positive HPV-associated cancers, and MicOryx, which targets microsatellite unstable (MSI-H) colorectal cancer. The company operates with a lean, capital-efficient business model, aiming to achieve clinical proof-of-concept before seeking pharmaceutical partnerships for late-stage development.